Back to search
FDAFDA · Food and drugs·Recall number D-0631-2018

Triamterene and Hydrochlorothiazide Tablets, USP, 75 mg/50 mg, 500-count bottles, Rx only, Manufactured by Sandoz, Inc., Princeton, NJ 08540, NDC 0781-5067-05.

Published April 25, 2018 · Recall initiated: April 6, 2018

Summary

FDA records drug Class III recall D-0631-2018, published April 25, 2018 and initiated April 6, 2018. Recalling firm: Sandoz Incorporated; Status: Terminated; Reported quantity: 11,680 bottles; Lot: Lot #: GW8264, HD3095, Exp 12/18. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cross Contamination With Other Products: presence of unrelated ingredients (i.e. traces of Lisinopril, Mannitol, Iron, Calcium and Phosphorous).

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sandoz Incorporated
Distributor
Nationwide in the USA and Puerto Rico
Lot
Lot #: GW8264, HD3095, Exp 12/18
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Triamterene and Hydrochlorothiazide Tablets, USP, 75 mg/50 mg, 500-count bottles, Rx only, Manufactured by Sandoz, Inc., Princeton, NJ 08540, NDC 0781-5067-05. recalled?

Yes. FDA published recall D-0631-2018 on April 25, 2018. Reported hazard: Cross Contamination With Other Products: presence of unrelated ingredients (i.e. traces of Lisinopril, Mannitol, Iron, Calcium and Phosphorous).

What should I do if I have this product?

Voluntary: Firm initiated · Letter